Haemonetics Corporation (HAE)
| Market Cap | 2.78B |
| Revenue (ttm) | 1.32B |
| Net Income (ttm) | 175.44M |
| Shares Out | 46.47M |
| EPS (ttm) | 3.65 |
| PE Ratio | 16.38 |
| Forward PE | 11.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 392,928 |
| Open | 61.20 |
| Previous Close | 60.48 |
| Day's Range | 59.68 - 62.18 |
| 52-Week Range | 47.32 - 87.32 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 84.13 (+40.73%) |
| Earnings Date | May 7, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.... [Read more]
Financial Performance
In fiscal year 2025, Haemonetics's revenue was $1.36 billion, an increase of 3.95% compared to the previous year's $1.31 billion. Earnings were $167.68 million, an increase of 42.64%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $84.13, which is an increase of 40.73% from the latest price.
News
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today a...
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May...
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology ...
Haemonetics Transcript: 47th Annual Raymond James Institutional Investor Conference
The conference highlighted record plasma business growth, successful innovation cycles, and robust financial performance, with strong share gains and new product launches like Persona PLUS and PerQseal Elite. The company is focused on sustainable growth, operational improvements, and disciplined capital deployment.
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today an...
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th An...
These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings
Haemonetics Corporation (NYSE: HAE) reported upbeat earnings for its third quarter on Thursday.
Haemonetics Earnings Call Transcript: Q3 2026
Strong Q3 results led to raised full-year guidance for revenue, earnings, and cash flow. Plasma and blood management technologies drove growth, while interventional technologies faced headwinds but are expected to recover in FY27. Margin expansion and robust cash flow support ongoing investments.
Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal...
Haemonetics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted strong financial performance, with high-margin growth driven by three core platforms: plasma, TEG, and vascular closure. Recent acquisitions and innovation pipelines are set to expand market leadership, while disciplined capital allocation supports future growth.
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic ho...
Vivasure Medical Announces Acquisition by Haemonetics Corporation
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemo...
Haemonetics Acquires Vivasure Medical Limited
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ann...
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026
BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, Febru...
Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francis...
Earn Twice The Yield You Get From Bank On HAE Stock
Currently priced at approximately $80.53 per share, Haemonetics (NYSE: HAE) is trading roughly 7.6% below its 52-week high.
Top 2 Health Care Stocks You May Want To Dump This Month
As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Haemonetics Earnings Call Transcript: Q2 2026
Second quarter results showed strong organic growth in core products, record margin expansion, and robust cash flow, leading to raised full-year guidance for revenue, EPS, and free cash flow. Plasma and blood management technologies outperformed, while targeted actions are underway to restore growth in interventional technologies.
Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON , Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fisc...
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025
BOSTON , Oct. 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, Nov...
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday.
Haemonetics Earnings Call Transcript: Q1 2026
Q1 saw 13% organic revenue growth ex-CSL, 8% adjusted EPS growth, and margin expansion, despite a 4% reported revenue decline from portfolio transitions. Guidance for the year is reaffirmed, with strong performance in Plasma and Hospital segments, and ongoing executional improvements in Interventional Technologies.
Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON , Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2026, which ended June ...
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025
BOSTON , July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, Augu...
Haemonetics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
A diversified medtech portfolio now drives double-digit earnings and robust cash flow, with plasma reduced to 38% of revenue and hospital platforms nearing 50%. The company targets high single-digit revenue and double-digit EPS growth, with continued margin expansion and a new three-year LRP to be detailed at an upcoming Investor Day.